NCT05465343

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial（iFORCE）

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Peking Union Medical College · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Conditions

• Furmonertinib
• EGFR-mutation
• NSCLC
• Brain Metastases

Interventions

Type	Name	Description
DRUG	Furmonertinib 160 mg, Q.D.	Furmonertinib 160 mg orally once daily in previously treated groups

Timeline

• Start date: 2022-07-11
• Primary completion: 2025-12-12
• Completion: 2025-12-12
• First posted: 2022-07-19
• Last updated: 2025-12-19

Locations

1 site across 1 country: China